COGNICURRENT

Jan 5 • 03:00 UTC • 🇨🇳 China • South China Morning Post

The ‘biology winter’ thaws: why investors are piling into Hong Kong’s biotech IPOs

Investors are increasingly supporting biotech IPOs in Hong Kong due to a resurgence in licensing deals and positive post-IPO performance, driving expectations of continued momentum through 2026.

#biotech #hong kong #ipo #investors #pharmaceuticals

Read Original Back to Feed

📡 Similar Coverage

🇨🇳 China Feb 10 • 05:00 UTC

Chinese investors pour into Hong Kong-listed drug stocks as international deals multiply

South China Morning Post

🇨🇳 China Jan 1 • 08:37 UTC

Why investors should remain bullish on Hong Kong, mainland stocks in 2026

South China Morning Post

🇨🇳 China Feb 4 • 23:30 UTC

Morgan Stanley sees another record year for Hong Kong IPOs as pipeline hits 450

South China Morning Post

🇨🇳 China Jan 8 • 10:40 UTC

Mainland Chinese medicine firms tap Hong Kong capital to fuel global expansion

South China Morning Post

🇨🇳 China Jan 14 • 23:30 UTC

Hong Kong, China stocks to outpace US equities all year after quick start, analysts say

South China Morning Post

🇵🇱 Poland Dec 30 • 05:03 UTC

Work is in full swing at brokerage offices. Will there be interesting IPOs in 2026?

Rzeczpospolita